Inhibrx Inc (INBX)
34.15
+0.14
(+0.41%)
USD |
NASDAQ |
May 03, 16:00
34.16
+0.01
(+0.03%)
After-Hours: 20:00
Inhibrx Free Cash Flow: -197.90M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -197.90M |
| September 30, 2023 | -168.51M |
| June 30, 2023 | -144.27M |
| March 31, 2023 | -128.90M |
| December 31, 2022 | -115.99M |
| September 30, 2022 | -108.01M |
| June 30, 2022 | -91.03M |
| March 31, 2022 | -86.58M |
| December 31, 2021 | -81.19M |
| September 30, 2021 | -74.30M |
| Date | Value |
|---|---|
| June 30, 2021 | -74.64M |
| March 31, 2021 | -63.52M |
| December 31, 2020 | -49.33M |
| September 30, 2020 | -45.61M |
| June 30, 2020 | -32.91M |
| March 31, 2020 | -35.71M |
| December 31, 2019 | -33.89M |
| September 30, 2019 | -35.13M |
| June 30, 2019 | -35.84M |
Free Cash Flow Range, Past 5 Years
-197.90M
Minimum
Dec 2023
-32.91M
Maximum
Jun 2020
-84.38M
Average
-74.64M
Median
Jun 2021
Free Cash Flow Benchmarks
| Axonics Inc | -16.29M |
| NovaBay Pharmaceuticals Inc | -4.15M |
| Palatin Technologies Inc | -26.75M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -19.20M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -56.82M |
| Cash from Investing (Quarterly) | -3.442M |
| Cash from Financing (Quarterly) | 0.86M |
| Free Cash Flow Per Share (Quarterly) | -1.114 |
| Free Cash Flow to Equity (Quarterly) | -61.51M |
| Free Cash Flow to Firm (Quarterly) | -56.74M |
| Free Cash Flow Yield | -12.30% |